Skip to main content
All lobbying filings

AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS

Lobbying for AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2025 · Illinois · House · Senate · $10,000.00 expenses · posted Apr 18, 2025

Official filing document

 Bills named in this filing 6
  • HR 1521
    DOC Access Act of 2025
  • HR 2028
    REDI Act
  • HR 1758
    Dental Loan Repayment Assistance Act of 2025
  • HR 879
    Medicare Patient Access and Practice Stabilization Act of 2025
  • HR 929
    Dr. Lorna Breen Health Care Provider Protection Reauthorization Act
  • S 266
    Dr. Lorna Breen Health Care Provider Protection Reauthorization Act
 Lobbying activity 4
Insurance

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees onnon-covered services Support for reintroduction of the Ensuring Lasting Smiles Act, which would require health insurers to cover treatment, including dental, for patientswith congenital craniofacial anomalies.

Education

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency. Support for H.R. 1758, the Dental Loan Repayment Assistance Act, which would allow full-time dental faculty members participating in the Health Resources and Services Administrations (HRSA) Dental Faculty Loan Repayment Program (DFLRP) to exclude from income the amount of their loan forgiveness from their federal income taxes.

Medicare/Medicaid

Support for H.R. 879, the bipartisan Medicare Patient Access and Practice Stabilization Act, which would halt the 2.83 percent Medicare physician payment cut and provide a 6.62 percent update through the end of the year to address inflationary pressures.

Health Issues

Support for the reintroduction of the following drug and supply bills from the 118th Congress: The RAPID Reserve Act, which aimed to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. The Mapping Americas Pharmaceutical Supply or MAPS Act, which sought to establish a comprehensive database to track the entire pharmaceutical supply chain. The Drug Shortages Prevention Act, which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages. The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 929/S. 266), which provides funding for programs that support mental healthcare for healthcare providers. Ask the EPA to appeal a US District Four ruling in Food & Water Watch v EPA regarding water fluoridation.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem